The technology presents a novel structural modification of an existing first generation Grp94 selective inhibitor to generate a second generation Grp94-specific scaffold which has greater affinity and selectivity compared to existing inhibitors and prevents unfavorable binding of other Hsp90 isoforms.
Unique chemical derivatives invented by University of Kansas (KU) researchers that could be used to detect inhibitors of cellular efflux transporters and other agents.
Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications. These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.
The invention describes CD44-selective nanovector systems for cancer-targeted delivery of molecular therapeutics.
A novel hair growth-enhancing formulation for the treatment of male pattern baldness (androgenic alopecia).
This invention is a system to deliver poorly permeable molecules into mammalian cells and avoid the problem of degradation.
This invention is a novel composition of matter that facilitates delivery of agents (e.g. diagnostic, therapeutic, imaging, etc.) into cells
This invention utilizes a delivery system that allows for a biologically relevant moiety to be delivered to a desired cell by utilizing a transporting agent that binds two receptors expressed by that cell. This decreases the toxicity that is shown by the active compound by delivering it only to a targeted cell.
This invention is a novel composition of matter that disrupts endosomes allowing for the release of biologically active agents into the cytosol.
This innovation has two forms: a hard capsule that dissolves orally and a film that dissolves orally. The capsules can be filled with a drug formulation containing an active drug or drugs, excipients, and flavors.